Lineage Cell Therapeutics Intangible Assets

As of the most recent data (June 2026), LCTX shows a intangible assets of $32M. That compares with $32M in the prior-year period — up 0.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LCTX's intangible assets is now $32M (was $32M) — essentially flat versus a year earlier. Pairing that YoY change with peer averages gives a clearer picture of whether Lineage Cell Therapeutics is outperforming or lagging.

Tracking LCTX's intangible assets over time shows whether Lineage Cell Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $32M That compares with $32M in the prior-year period — up 0.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this intangible assets page, Stockcircle has Lineage Cell Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect intangible assets (currently $32M) with ownership activity and broader fundamentals.

Lineage Cell Therapeutics's intangible assets is $32M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.